MARKET

SLNO

SLNO

SOLENO THERAPEUT
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.9300
+0.0093
+1.01%
After Hours: 0.9400 +0.01 +1.08% 19:12 07/29 EDT
OPEN
0.9200
PREV CLOSE
0.9207
HIGH
0.9550
LOW
0.9200
VOLUME
313.10K
TURNOVER
--
52 WEEK HIGH
3.360
52 WEEK LOW
0.8900
MARKET CAP
74.18M
P/E (TTM)
-2.2399
1D
5D
1M
3M
1Y
5Y
BRIEF-Soleno Therapeutics Q2 Loss Per Share $0.14
reuters.com · 1d ago
BRIEF-Soleno Therapeutics Provides Corporate Update And Reports Second Quarter 2021 Financial Results
reuters.com · 1d ago
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26)
Benzinga · 2d ago
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19)
Benzinga · 07/20 12:19
Stocks That Hit 52-Week Lows On Monday
  Stocks That Hit 52-Week Lows On Monday Monday morning, 285 companies reached new 52-week lows.
Benzinga · 07/19 14:04
BRIEF-Soleno Therapeutics - On July 16 Entered Into Controlled Equity Offering Sales Agreement With Cantor Fitzgerald
reuters.com · 07/16 20:18
FDA maintains additional trial necessary for Soleno's Prader-Willi Syndrome candidate
Sarah Silbiger/Getty Images News The FDA has again informed Soleno Therapeutics ([[SLNO]] -1.8%) that an additional clinical trial is necessary for in order to submit an NDA for once-daily DCCR
Seekingalpha · 07/06 16:10
BRIEF-Soleno Therapeutics Provides Regulatory Update On Dccr For The Treatment Of Prader-Willi Syndrome
reuters.com · 07/06 12:38
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SLNO. Analyze the recent business situations of SOLENO THERAPEUT through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SLNO stock price target is 6.00 with a high estimate of 7.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 83
Institutional Holdings: 32.93M
% Owned: 41.29%
Shares Outstanding: 79.76M
TypeInstitutionsShares
Increased
20
1.22M
New
8
381.54K
Decreased
22
4.03M
Sold Out
12
9.57M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.31%
Key Executives
Non-Executive Chairman/Independent Director
Ernest Mario
President/Chief Executive Officer/Chief Operating Officer/Director
Anish Bhatnagar
Chief Financial Officer
James Mackaness
Vice President
Patricia Hirano
Vice President
Kristen Yen
Independent Director
William Harris
Independent Director
Gwen Melincoff
Independent Director
Andrew Sinclair
Independent Director
Birgitte Volck
No Data
  • All
  • Financials
  • Insiders
More
About SLNO
Soleno Therapeutics, Inc., formerly Capnia, Inc., is a healthcare company that develops and commercializes neonatology devices and diagnostics. The Company also has a therapeutics platform based on its proprietary technology for precision metering of gas flow. The Company offers products, such as CoSense end-tidal carbon monoxide (ETCO) Monitor, NeoPIP Infant Resuscitator and Accessories, and Serenz Nasal Relief. The Company has developed the CoSense End-Tidal Carbon Monoxide Monitor that measures ETCO for the detection of dangerous hemolysis rates. The Infant Solutions product line, including the NeoPIP Infant Resuscitator Unit and accessories, is designed for controlled and accurate resuscitation of neonates and infants in the clinical environment. Serenz Nasal Relief is a hand-held nasal irrigator that uses carbon dioxide (CO2) gas to wash the nasal passages.

Webull offers kinds of Soleno Therapeutics Inc stock information, including NASDAQ:SLNO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLNO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SLNO stock methods without spending real money on the virtual paper trading platform.